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3. Progress Report. 
Overall Objectives for Total Project. A number of proteolytic enzymes such as 
elastase and collagenase have been shown to be involved in diseases such as pulmonary 
emphysema and arthritis which involve tissue destruction. The goal of this proposed 
research is to design and synthesize specific and effective inhibitors for these pro-
teolytic enzymes. The inhibitors should be invaluable in the study of the normal bio-
logical function and the role of these proteases in disease. In addition, synthetic 
protease inhibitors should find use in the clinical treatment of plumonary emphysema, 
rheumatoid arthritis and other diseases. 
Goals for the Current Year. Our goals for the current year were to develop new 
types of inhibitors for human leukocyte elastase (a serine protease) and to continue work 
on developing specific metalloprotease inhibitors. 
Studies with Human Granulocyte Enzymes. Proteolysis by enzymes released from human 
PMN leukocytes, macrophages and other sources are involved in several major diseases which 
involve tissue destruction. In the case of pulmonary emphysema, elastase seems to be 
principally responsible for lung damage with collagenase, cathepsin G and other proteases 
carrying out secondary digestions. We have previously synthesized a number of specific 
peptide chloromethyl ketone inhibitors of both human leukocyte elastase and cathepsin 
G. Three of the best elastase inhibitors, Me0-Suc-Ala-Ala-Pro-Va1CH 2C1, Suc-Ala-Ala-Pro-
Va1CH2 Cl and Ac-Ala-Ala-Pro-AlaCH 2Cl, have been shown to be effective at preventing 
emphysema by three research groups (Dr. Aaron Janoff, SUNY Stoney Brook; Dr. P. Stone, 
Boston University; and Dr. J. Kleinerman, Mt. Sinai Medical Center). In all cases the 
hamster emphysema animal model was utilized. Even though our peptide chloromethyl ketones 
are effective, there has been considerable concern about their toxicity. Chloromethyl 
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ketones are alkylating agents and would be expected to exhibit some carcinogencity. 
Thus most investigators believe that these compounds may not have utility for the 
treatment of human disease. Therefore, we have begun a search for specific elastase 
inhibitors which have properties which would allow their utilization in humans. 
We have been investigating sulfonyl fluorides as elastase inhibitors and have 






I 	wg to (4-F3.) 	 It 
	NH 
HL elastase 	 1700 	 1400 	 1200 
PP elastase 1300 62 26 
cathepsin G 	 13 	 5.8 	 13 
The values listed under each compound are inhibition rates (k
obs
/[I]). These compounds 
are simply representatives of many sulfonyl fluorides which we have synthesized and 
tested. All three are very effective inhibitors of human leukocyte elastase and the 
latter two are quite specific. Sulfonyl fluorides are not generally considered to be 
toxic and thus elastase inhibitors such as these may find utility in the treatment of 
human disease. P. Stone and J. Kleinerman have agreed to test a sulfonyl fluoride in 
their animal models of emphysema. 
Our goals for next year are to improve the reactivity and specificity of this class 
of compounds. Many of the sulfonyl fluorides hydrolyze quite rapidly in water and we 
plan to synthesize analogues which may exhibit greater stability toward hydrolysis. 
Small Peptide Analogs of the a l-Protease Inhibitor. Another approach to elastase 
inhibitors is to make analogs of the a-protease inhibitor (a l-antitrypsin) active site. 
The sequence at the active site has recently been determined by Dr. J. Travis at the U. 
GA. We were then able to design and synthesize small cyclic peptides such as 1 which 
have the a 1
-PI active site sequence. This peptide is a reversible inhibitor of human 
leukocyte elastase (K1 = 0.38mM) and is not a substrate. We then replaced the Met-Thr 
Ala-Leu-Pro-Met-Thr-Leu 	 Ala-Leu-Pro-Val-Ser-Leu 
 
	Abz-Abz 
       




        
Abz = 3-aminobenzoyl 
residues with Val-Ser to get '2 which was a poorer inhibitor (K
I 
= 0.30mM). However, a 
minor by-product of the reaction was a 20-fold better inhibitor (K I = 0.040mM). At 
present, we are uncertain as to the structure of the by-product, but suspect racemization 
at the Ala residue. 
Although the cyclic peptides are only moderate inhibitors at present, they are good 
lead compounds for the development of better structures. Our first goal for the next 
year is to determine the structure of the by-product which is the best HL elastase of 




close resemblance to the natural inhibitor. Synthetic elastase inhibitors seem to 
offer the best hope at present for the treatment of the majority of emphysema since 
natural a l -PI is difficult to isolate and purify. 
Studies with Metalloproteases. A number of metalloproteases are involved in 
diseases which involve connective tissue destruction. Collagenase has been found in 
rheumatoid synovium and has been implicated in the destruction of joints in rheumatoid 
arthritis. Collagenase may also be involved in periodontal disease, corneal ulceration, 
and several other diseases. Invasive tumors have been shown to secrete collagenase 
and the ability of this enzyme to attack connective tissue may allow such tumors to 
expand into the surrounding tissue. 
Excellent progress has been made in the development of general classes of in-
hibitors for the metalloproteases family. Using thermolysin and carboxypeptidase as 
model systems in our initial experiments, we have investigated phosphoramidates, 
hydroxamq acids as irreversible inhibitors. Phosphoramidates such as P-Leu-NH 2 and 
P-Phe-O K are excellent inhibitors of thermolysin and carboxypeptidase A respectively. 






)C0-) is a specific in-
hibitor of thermolysin (K
I 
= 0.7 pM) and has been attached to agarose and used in the 













have been designed and synthesized. The site 
reaction has been determined. Several hydroxamic acids thiols, and phosphoramidates 
with the appropriate sequence to inhibit collagenase have been synthesized. Some were 
observed to be moderate inhibitors. 
Pseudomonas aeruginosa elastase is an infectious organism which is resistant to 
many antibiotics. This organism causes hemorrhagic pneumonia in mink and corneal ulcers 
in man. The major cause of morbidity and mortality in cystic fibrosis is the severe, 
chronic presistent pulmonary infection with bacteria particularily P. aeruginosa. Many 
strains of P. aeruginosa produce an elastase. Those strains with elastase have been 
shown to be more pathogenic than those without. The elastase is likely the factor re-
sponsible for the destruction of corneal tissue and hemorrhages of the lung observed in 
P. aeruginosa infections. 
P. aeruginosa is a zinc metalloprotease and we have developed a new substrate to 
assay the enzyme. Specific inhibitors for this elastase have been designed and syn-
thesized. In particular, the hydroxamic acid HONH-COCH 9CH(CHC 6Hc )CO-Ala-Gly-NH2 was 
a potent reversible inhibitor (K., = 0.044 pM) and ClCy0-HO-teu-Ala-Gly-NR 2 was 
an irreversible inhibitor. Both compounds may find utility in the treatment of infec-
tions due to P. aeruginosa elastase. 
Our goals for next year are to extend inhibitors to collagenase and improve the 
inhibitor for P.a. elastase. In particular, a more effective irreversible inhibitor 
is needed and we plan to synthesize and test compounds such as CH2=CH-CO-HOLeu-Ala-Gly- 
NH2 . 
Significance. It is the belief of the author that reagents which control the 
activity of proteolytic enzymes can be used in a number of clinical situations. Diseases 
involving tissue destruction such as emphysema and arthritis have been shown to involve 
enzymes such as elastase, cathepsin G and collagenase. Invasive tumors secrete colla-
genase, possibly accounting for their ability to expand into the surrounding connective 
tissue. Viral protein processing requires a protease. Organisms like Neisseria  
Gonorrhoeae and N. meningitidis secrete proteases which cleave the principal mucosal 
antibody, immunoglobulin A., and P. aeruginosa produces an enzyme which destroys lung 
tissue. 
The basic goal of our research is to develop new classes of inhibitors for the two 
major families of proteases: serine and metalloproteases. Within this framework our 
emphasis have been directed toward inhibitors for granulocyte elastase and cathepsin G, 
and collagenase since these enzymes are involved in two major chronic diseases: emphysema 




specific enzymes and about the two general classes of proteases. In addition, we are 
discovering ways to increase the specificity of inhibitors both for a specific enzyme 
within a class of proteases and for an enzyme when it is located in its natural enviro-
ment which may contain a multitude of other reactive groups. The information should 
be useful to other investigators who desire specific inhibitors for other proteases. 
At present some of our elastase inhibitors are being tested in animals for the 
treatment of emphysema. In fact, we are currently synthesizing 9..g of a chloromethyl 
ketone elastase inhibitor in order for J. Kleinerman (Mt. Sinai Med. Center) to carry 
out a 6-month study of the effect of daily doses of the inhibitor on the progression 
of emphysema in hamsters. There is a good possibility that the course of emphysema 
can be arrested by use of the appropriate inhibitor. At present, better elastase in-
hibitors are desired. Our studies with synthetic protease inhibitors are leading us 
closer to clinically useful drugs. 
The undersigned agrees to accept responsibility for the scientific technical 
conduct of the project and for provision of required progress reports if a grant 
is awarded as the result of this application. 
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